X4 Pharmaceuticals XFOR Institutional Ownership

X4 Pharmaceuticals, Inc (NASDAQ:XFOR) showed up in the 13F filings of 90 institutional investors as of June 2026.

• These investors collectively held 78.7% of X4 Pharmaceuticals's outstanding shares in June 2026, up from 74.4% in March 2026.
• They increased total shares held in X4 Pharmaceuticals by 9.97% from the prior quarter, while the number of investors in XFOR increased 76.47% year over year.
• During the quarter, 57 of these 90 funds increased positions in XFOR, 13 reduced exposure, and 20 held steady.
• In total, institutional investors held 99.42Mn shares in X4 Pharmaceuticals as of June 2026, up by 9.01Mn shares quarter on quarter, and up 96.59Mn shares year over year.
• Morgan Stanley leads ownership in XFOR with 9.46Mn shares as of June 30, 2026, equal to 7.49% of outstanding shares.
• The largest buyers of X4 Pharmaceuticals for the quarter ending June 2026 were BlackRock, Inc. (4.34Mn), Venrock Adviser, LLC (1.6Mn), PERCEPTIVE ADVISORS LLC (1.2Mn), GEODE CAPITAL MANAGEMENT, LLC (1.16Mn), State Street Corp (892.48K).
• The biggest sellers of X4 Pharmaceuticals for the quarter ending June 2026 included Empery Asset Management, LP (2.01Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (842.17K), Deep Track Capital, LP (460.78K), Samsara BioCapital, LLC (436.98K), BRAIDWELL LP (350.2K).
• According to Business Quant data, leading holders of XFOR for June 2026 are Morgan Stanley (9.46Mn), FMR LLC (8.32Mn), Bain Capital Life Sciences Investors, LLC (7.97Mn), PERCEPTIVE ADVISORS LLC (7.93Mn), Saturn V Capital Management LP (6.97Mn), Empery Asset Management, LP (6.93Mn), Deep Track Capital, LP (5.88Mn), BlackRock, Inc. (5.55Mn), Kalehua Capital Management LLC (3.72Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.72Mn).